학술논문
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
Document Type
Article
Author
Pfisterer, J.; Joly, F.; Kristensen, G.; Rau, J.; Mahner, S.; Burges, A.; Pautier, P.; El-Balat, A.; Kurtz, J.-E.; Canzler, U.; Sehouli, J.; Heubner, M.L.; Hartkopf, A.D.; Baumann, K.; Hasenburg, A.; Hanker, L.C.; Belau, A.; Schmalfeldt, B.; Denschlag, D.; Park-Simon, T.-W.; Selle, F.; Jackisch, C.; Lück, H.-J.; Emons, G.; Meier, W.; Gropp-Meier, M.; Schröder, W.; De Gregorio, N.; Hilpert, F.; Harter, P.
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 1 February 2023, 41(4):893-902)
Subject
Language
English
ISSN
15277755
0732183X
0732183X